vs

Side-by-side financial comparison of Adobe Inc. (ADBE) and Bristol Myers Squibb (BMY). Click either name above to swap in a different company.

Bristol Myers Squibb is the larger business by last-quarter revenue ($12.5B vs $6.4B, roughly 2.0× Adobe Inc.). Adobe Inc. runs the higher net margin — 29.5% vs 8.7%, a 20.8% gap on every dollar of revenue. On growth, Adobe Inc. posted the faster year-over-year revenue change (12.0% vs 1.3%). Adobe Inc. produced more free cash flow last quarter ($2.9B vs $1.6B). Over the past eight quarters, Adobe Inc.'s revenue compounded faster (9.8% CAGR vs 2.6%).

Adobe Inc., formerly Adobe Systems Incorporated, is an American multinational computer software company based in San Jose, California. It offers a wide range of programs from web design tools, photo manipulation, and vector creation to video and audio editing, mobile app development, print layout, and animation software.

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...

ADBE vs BMY — Head-to-Head

Bigger by revenue
BMY
BMY
2.0× larger
BMY
$12.5B
$6.4B
ADBE
Growing faster (revenue YoY)
ADBE
ADBE
+10.7% gap
ADBE
12.0%
1.3%
BMY
Higher net margin
ADBE
ADBE
20.8% more per $
ADBE
29.5%
8.7%
BMY
More free cash flow
ADBE
ADBE
$1.3B more FCF
ADBE
$2.9B
$1.6B
BMY
Faster 2-yr revenue CAGR
ADBE
ADBE
Annualised
ADBE
9.8%
2.6%
BMY

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ADBE
ADBE
BMY
BMY
Revenue
$6.4B
$12.5B
Net Profit
$1.9B
$1.1B
Gross Margin
89.6%
67.2%
Operating Margin
37.8%
11.8%
Net Margin
29.5%
8.7%
Revenue YoY
12.0%
1.3%
Net Profit YoY
4.3%
1409.7%
EPS (diluted)
$4.60
$0.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ADBE
ADBE
BMY
BMY
Q1 26
$6.4B
Q4 25
$6.2B
$12.5B
Q3 25
$6.0B
$12.2B
Q2 25
$5.9B
$12.3B
Q1 25
$5.7B
$11.2B
Q4 24
$5.6B
$12.3B
Q3 24
$5.4B
$11.9B
Q2 24
$5.3B
$12.2B
Net Profit
ADBE
ADBE
BMY
BMY
Q1 26
$1.9B
Q4 25
$1.9B
$1.1B
Q3 25
$1.8B
$2.2B
Q2 25
$1.7B
$1.3B
Q1 25
$1.8B
$2.5B
Q4 24
$1.7B
$72.0M
Q3 24
$1.7B
$1.2B
Q2 24
$1.6B
$1.7B
Gross Margin
ADBE
ADBE
BMY
BMY
Q1 26
89.6%
Q4 25
89.5%
67.2%
Q3 25
89.3%
71.9%
Q2 25
89.1%
72.5%
Q1 25
89.1%
72.9%
Q4 24
89.0%
61.0%
Q3 24
89.8%
75.1%
Q2 24
88.7%
73.2%
Operating Margin
ADBE
ADBE
BMY
BMY
Q1 26
37.8%
Q4 25
36.5%
11.8%
Q3 25
36.3%
25.5%
Q2 25
35.9%
14.5%
Q1 25
37.9%
26.5%
Q4 24
34.9%
1.4%
Q3 24
36.8%
14.1%
Q2 24
35.5%
10.5%
Net Margin
ADBE
ADBE
BMY
BMY
Q1 26
29.5%
Q4 25
30.0%
8.7%
Q3 25
29.6%
18.0%
Q2 25
28.8%
10.7%
Q1 25
31.7%
21.9%
Q4 24
30.0%
0.6%
Q3 24
31.1%
10.2%
Q2 24
29.6%
13.8%
EPS (diluted)
ADBE
ADBE
BMY
BMY
Q1 26
$4.60
Q4 25
$4.44
$0.54
Q3 25
$4.18
$1.08
Q2 25
$3.94
$0.64
Q1 25
$4.14
$1.20
Q4 24
$3.75
$0.05
Q3 24
$3.76
$0.60
Q2 24
$3.49
$0.83

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ADBE
ADBE
BMY
BMY
Cash + ST InvestmentsLiquidity on hand
$6.9B
$10.2B
Total DebtLower is stronger
$5.4B
$44.8B
Stockholders' EquityBook value
$11.4B
$18.5B
Total Assets
$29.7B
$90.0B
Debt / EquityLower = less leverage
0.47×
2.43×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ADBE
ADBE
BMY
BMY
Q1 26
$6.9B
Q4 25
$6.6B
$10.2B
Q3 25
$5.9B
$15.7B
Q2 25
$5.7B
$12.6B
Q1 25
$7.4B
$10.9B
Q4 24
$7.9B
$10.3B
Q3 24
$7.5B
$7.9B
Q2 24
$8.1B
$6.3B
Total Debt
ADBE
ADBE
BMY
BMY
Q1 26
$5.4B
Q4 25
$6.2B
$44.8B
Q3 25
$6.2B
$48.7B
Q2 25
$6.2B
$48.9B
Q1 25
$6.2B
$49.5B
Q4 24
$4.1B
$49.4B
Q3 24
$4.1B
$49.5B
Q2 24
$4.1B
$52.0B
Stockholders' Equity
ADBE
ADBE
BMY
BMY
Q1 26
$11.4B
Q4 25
$11.6B
$18.5B
Q3 25
$11.8B
$18.6B
Q2 25
$11.4B
$17.4B
Q1 25
$13.1B
$17.4B
Q4 24
$14.1B
$16.3B
Q3 24
$14.5B
$17.1B
Q2 24
$14.8B
$17.0B
Total Assets
ADBE
ADBE
BMY
BMY
Q1 26
$29.7B
Q4 25
$29.5B
$90.0B
Q3 25
$28.8B
$96.9B
Q2 25
$28.1B
$94.7B
Q1 25
$30.0B
$92.4B
Q4 24
$30.2B
$92.6B
Q3 24
$29.8B
$93.7B
Q2 24
$30.0B
$94.6B
Debt / Equity
ADBE
ADBE
BMY
BMY
Q1 26
0.47×
Q4 25
0.53×
2.43×
Q3 25
0.53×
2.63×
Q2 25
0.54×
2.81×
Q1 25
0.47×
2.85×
Q4 24
0.29×
3.03×
Q3 24
0.28×
2.89×
Q2 24
0.28×
3.05×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ADBE
ADBE
BMY
BMY
Operating Cash FlowLast quarter
$3.0B
$2.0B
Free Cash FlowOCF − Capex
$2.9B
$1.6B
FCF MarginFCF / Revenue
45.7%
12.8%
Capex IntensityCapex / Revenue
0.6%
3.0%
Cash ConversionOCF / Net Profit
1.57×
1.82×
TTM Free Cash FlowTrailing 4 quarters
$10.3B
$12.8B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ADBE
ADBE
BMY
BMY
Q1 26
$3.0B
Q4 25
$3.2B
$2.0B
Q3 25
$2.2B
$6.3B
Q2 25
$2.2B
$3.9B
Q1 25
$2.5B
$2.0B
Q4 24
$4.4B
Q3 24
$2.0B
$5.6B
Q2 24
$1.9B
$2.3B
Free Cash Flow
ADBE
ADBE
BMY
BMY
Q1 26
$2.9B
Q4 25
$3.1B
$1.6B
Q3 25
$2.1B
$6.0B
Q2 25
$2.1B
$3.6B
Q1 25
$2.5B
$1.7B
Q4 24
$4.1B
Q3 24
$2.0B
$5.3B
Q2 24
$1.9B
$2.1B
FCF Margin
ADBE
ADBE
BMY
BMY
Q1 26
45.7%
Q4 25
50.5%
12.8%
Q3 25
35.5%
49.0%
Q2 25
36.5%
29.0%
Q1 25
43.0%
15.1%
Q4 24
32.9%
Q3 24
36.3%
44.3%
Q2 24
35.8%
16.9%
Capex Intensity
ADBE
ADBE
BMY
BMY
Q1 26
0.6%
Q4 25
0.5%
3.0%
Q3 25
1.2%
2.6%
Q2 25
0.8%
2.9%
Q1 25
0.5%
2.3%
Q4 24
3.1%
Q3 24
1.1%
2.7%
Q2 24
0.8%
2.1%
Cash Conversion
ADBE
ADBE
BMY
BMY
Q1 26
1.57×
Q4 25
1.70×
1.82×
Q3 25
1.24×
2.87×
Q2 25
1.30×
2.99×
Q1 25
1.37×
0.80×
Q4 24
61.65×
Q3 24
1.20×
4.62×
Q2 24
1.23×
1.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ADBE
ADBE

Subscription Revenue$6.2B97%
Service Other$110.0M2%
Products$90.0M1%

BMY
BMY

Net Product Sales$12.1B97%
Zeposia$159.0M1%
Opdivo Ovantig$132.0M1%
Abecma$100.0M1%
Sotyktu$86.0M1%

Related Comparisons